{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Duarte G"],"funding":["Eunice Kennedy Shriver National Institute of Child Health and Human Development","NICHD NIH HHS"],"pagination":["1021-1031"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8921998"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["225(6)"],"pubmed_abstract":["<h4>Background</h4>Pneumococcal vaccination is recommended in people with HIV, prioritizing PCV. We compared the immunogenicity of PCV-10 and PPV-23 administered antepartum or postpartum.<h4>Methods</h4>This double-blind study randomized 346 pregnant women with HIV on antiretrovirals to PCV-10, PPV-23, or placebo at 14-34 weeks gestational age. Women who received placebo antepartum were randomized at 24 weeks postpartum to PCV-10 or PPV-23. Antibodies against 7 serotypes common to both vaccines and 1 serotype only in PPV-23 were measured by ELISA/chemiluminescence; B- and T-cell responses to serotype 1 by FLUOROSPOT; and plasma cytokines/chemokines by chemiluminescence.<h4>Results</h4>Antibody responses were higher after postpartum versus antepartum vaccination. PCV-10 generated lower antibody levels than PPV-23 against 4 and higher against 1 of 7 common serotypes. Additional factors associated with high postvaccination antibody concentrations were high prevaccination antibody concentrations and CD4+ cells; low CD8+ cells and plasma HIV RNA; and several plasma cytokines/chemokines. Serotype 1 B- and T-cell memory did not increase after vaccination.<h4>Conclusions</h4>Antepartum immunization generated suboptimal antibody responses, suggesting that postpartum booster doses may be beneficial and warrant further studies. Considering that PCV-10 and PPV-23 had similar immunogenicity, but PPV-23 covered more serotypes, use of PPV-23 may be prioritized in women with HIV on antiretroviral therapy.<h4>Clinical trails registration</h4>NCT02717494."],"journal":["The Journal of infectious diseases"],"pubmed_title":["Immunogenicity of Conjugated and Polysaccharide Pneumococcal Vaccines Administered During Pregnancy or Postpartum to Women With HIV."],"pmcid":["PMC8921998"],"funding_grant_id":["HHSN275201800001I","HHSN275201800001C"],"pubmed_authors":["Canniff J","Machado ES","Pelton SI","Coutinho CM","Bone F","Newton L","Golner A","Mussi-Pinhata MM","Santos BR","Fenton T","Joao EC","Chakhtoura N","Ward S","Pinto JA","Duarte G","Weinberg A","Laimon L","Muresan P","Pilotto JH","Oliveira RH","Kreitchman R"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity of Conjugated and Polysaccharide Pneumococcal Vaccines Administered During Pregnancy or Postpartum to Women With HIV.","description":"<h4>Background</h4>Pneumococcal vaccination is recommended in people with HIV, prioritizing PCV. We compared the immunogenicity of PCV-10 and PPV-23 administered antepartum or postpartum.<h4>Methods</h4>This double-blind study randomized 346 pregnant women with HIV on antiretrovirals to PCV-10, PPV-23, or placebo at 14-34 weeks gestational age. Women who received placebo antepartum were randomized at 24 weeks postpartum to PCV-10 or PPV-23. Antibodies against 7 serotypes common to both vaccines and 1 serotype only in PPV-23 were measured by ELISA/chemiluminescence; B- and T-cell responses to serotype 1 by FLUOROSPOT; and plasma cytokines/chemokines by chemiluminescence.<h4>Results</h4>Antibody responses were higher after postpartum versus antepartum vaccination. PCV-10 generated lower antibody levels than PPV-23 against 4 and higher against 1 of 7 common serotypes. Additional factors associated with high postvaccination antibody concentrations were high prevaccination antibody concentrations and CD4+ cells; low CD8+ cells and plasma HIV RNA; and several plasma cytokines/chemokines. Serotype 1 B- and T-cell memory did not increase after vaccination.<h4>Conclusions</h4>Antepartum immunization generated suboptimal antibody responses, suggesting that postpartum booster doses may be beneficial and warrant further studies. Considering that PCV-10 and PPV-23 had similar immunogenicity, but PPV-23 covered more serotypes, use of PPV-23 may be prioritized in women with HIV on antiretroviral therapy.<h4>Clinical trails registration</h4>NCT02717494.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-06-18T07:00:04.7Z","creation":"2025-04-05T11:57:09.539Z"},"accession":"S-EPMC8921998","cross_references":{"pubmed":["34791324"],"doi":["10.1093/infdis/jiab567"]}}